Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells

DNA methyltransferases (DNMTs) are important enzymes involved in epigenetic control of gene expression and represent valuable targets in cancer chemotherapy. A number of nucleoside DNMT inhibitors (DNMTi) have been studied in cancer, including in cancer stem cells, and two of them (azacytidine and decitabine) have been approved for treatment of myelodysplastic syndromes. However, only a few non-nucleoside DNMTi have been identified so far, and even fewer have been validated in cancer. Through a process of hit-to-lead optimization, we report here the discovery of compound 5 as a potent non-nucleoside DNMTi that is also selective toward other AdoMet-dependent protein methyltransferases. Compound 5 was potent at single-digit micromolar concentrations against a panel of cancer cells and was less toxic in peripheral blood mononuclear cells than two other compounds tested. In mouse medulloblastoma stem cells, 5 inhibited cell growth, whereas related compound 2 showed high cell differentiation. To the best of our knowledge, 2 and 5 are the first non-nucleoside DNMTi tested in a cancer stem cell line.

[1]  A. Sakharkar,et al.  Regulation of DNA methylation by ethanol induces tissue plasminogen activator expression in astrocytes , 2014, Journal of neurochemistry.

[2]  Jiang Wu,et al.  Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy , 2008, Medicinal research reviews.

[3]  M. Diederich,et al.  Epigenomics of leukemia : from mechanisms to therapeutic applications Review , 2009 .

[4]  A. Guidotti,et al.  Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice , 2013, Neuropharmacology.

[5]  Yupo Ma,et al.  Stem Cell Gene SALL4 Suppresses Transcription through Recruitment of DNA Methyltransferases* , 2011, The Journal of Biological Chemistry.

[6]  Peter A. Jones,et al.  Epigenetic therapy of cancer: past, present and future , 2006, Nature Reviews Drug Discovery.

[7]  Xing Zhang,et al.  Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. , 2003, Structure.

[8]  J. Snyder,et al.  Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294 , 2009, Nature Structural &Molecular Biology.

[9]  Terence Dwyer,et al.  American Journal of Epidemiology Review Prospects for Epigenetic Epidemiology , 2022 .

[10]  Mauro Biffoni,et al.  Hedgehog controls neural stem cells through p53‐independent regulation of Nanog , 2010, The EMBO journal.

[11]  M. Diederich,et al.  DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. , 2012, Biochemical pharmacology.

[12]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[13]  M. Esteller,et al.  Aberrant DNA methylation profiles in the premature aging disorders Hutchinson-Gilford Progeria and Werner syndrome , 2013, Epigenetics.

[14]  K. Ghoshal,et al.  A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. , 2009, Cancer research.

[15]  A. Jeltsch,et al.  Rapid Synthesis of New DNMT Inhibitors Derivatives of Procainamide , 2012, Chembiochem : a European journal of chemical biology.

[16]  D. Patel,et al.  Structure of DNMT1-DNA Complex Reveals a Role for Autoinhibition in Maintenance DNA Methylation , 2011, Science.

[17]  P. Arimondo,et al.  Development of a universal radioactive DNA methyltransferase inhibition test for high-throughput screening and mechanistic studies , 2013, Nucleic acids research.

[18]  A. Dueñas-González,et al.  Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial , 2010, Annals of Hematology.

[19]  M. Diederich,et al.  Chromatin-modifying agents in anti-cancer therapy. , 2012, Biochimie.

[20]  A. Jeltsch,et al.  Structure and Function of Mammalian DNA Methyltransferases , 2011, Chembiochem : a European journal of chemical biology.

[21]  S. Pradhan,et al.  CXXC domain of human DNMT1 is essential for enzymatic activity. , 2008, Biochemistry.

[22]  R. Copeland,et al.  Kinetic effects due to nonspecific substrate-inhibitor interactions in enzymatic reactions. , 1998, Biochemical pharmacology.

[23]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[24]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[25]  A. Yee,et al.  HBP1-Mediated Transcriptional Regulation of DNA Methyltransferase 1 and Its Impact on Cell Senescence , 2012, Molecular and Cellular Biology.

[26]  Rochelle L. Tiedemann,et al.  Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells. , 2012, Cell reports.

[27]  Robert A Copeland,et al.  Mechanistic considerations in high-throughput screening. , 2003, Analytical biochemistry.

[28]  X. Zhang,et al.  Structure of the Predominant protein arginine methyltransferase PRMT1 , 2003 .

[29]  T. Sugai,et al.  Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy , 2007, International journal of cancer.

[30]  C. Brennan,et al.  Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine , 2013, Oncotarget.

[31]  M. Diederich,et al.  Sustained exposure to the DNA demethylating agent, 2'-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy. , 2011, Biochemical pharmacology.

[32]  Y. Shinkai,et al.  H3K9 methyltransferase G9a and the related molecule GLP. , 2011, Genes & development.

[33]  K. Cherubini,et al.  The role of epigenetic transcription repression and DNA methyltransferases in cancer , 2011, Cancer.

[34]  A. Jeltsch,et al.  C5‐DNA Methyltransferase Inhibitors: From Screening to Effects on Zebrafish Embryo Development , 2011, Chembiochem : a European journal of chemical biology.

[35]  Xin Wang,et al.  Cancer prevention by tea: animal studies, molecular mechanisms and human relevance , 2009, Nature Reviews Cancer.

[36]  Jean-Marc Gregoire,et al.  DNA methylation inhibitors in cancer: recent and future approaches. , 2012, Biochimie.

[37]  Xiaodong Cheng,et al.  Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation , 2012, Nucleic acids research.

[38]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[39]  G. Firestein,et al.  Regulation of DNA Methylation in Rheumatoid Arthritis Synoviocytes , 2013, The Journal of Immunology.

[40]  Shih‐Ann Chen,et al.  Heart failure and angiotensin II modulate atrial Pitx2c promotor methylation , 2013, Clinical and experimental pharmacology & physiology.

[41]  J. Medina-Franco,et al.  Synthesis and biochemical evaluation of δ(2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors. , 2011, Journal of medicinal chemistry.

[42]  A. Bird,et al.  DNA methylation and chromatin modification. , 1999, Current opinion in genetics & development.

[43]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.